Blood Plasma Market size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin, Albumin, Protease Inhibitors, Coagulation Factor Concentrates, Others) By Application (Hospitals and Clinics, Research Laboratories, Academic Institutions), and Regional Forecast to 2032

• 

  Request a Free Sample to learn more about this report

BLOOD PLASMA MARKET OVERVIEW

The Global Blood Plasma Market size was USD 39275.84 million in 2023 and is projected to touch USD 94078.84 million by 2032, exhibiting a CAGR of 10.19% during the forecast period.

There are high prospects for the market due to the growing requirement of plasma-derived therapies meant for life-threatening conditions in relation to immune disorders, hemophilia, and various forms of liver diseases. Plasma, which contains several critical proteins such as albumin, immunoglobulins, and clotting factors, is essential to treatment in a variety of medical conditions. Advances made in the technology of plasma collection, fractionation, and processing have improved both efficiency and safety of the products obtained from plasma. Other factors driving this market include an increasing incidence of chronic diseases, a general trend of an aging population, and the development of health care infrastructure in emerging economies. Though encountering issues of high costs and regulatory problems, the funds invested in R&D and the expansion of plasma collection centers would continue to drive growth in this sector.

GLOBAL CRISES IMPACTING BLOOD PLASMA MARKET - COVID-19 IMPACT

"Blood Plasma Market Had a Positive Effect Due to Increased Awareness of Plasma's Therapeutic Potential, Especially for Immune and Infectious Diseases during COVID-19 Pandemic."

The Global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The pandemic of COVID-19 specially hit the Blood Plasma Market. The blood plasma market has been the most affected market by COVID-19. General lockdown, restrictions, and poor turnout of donors have resulted in disruptions in the collection and donation process for blood plasma, thus giving rise to a plasma supply deficit that has directly affected plasma-derived therapies. Moreover, COVID-19 brought attention to plasma in therapeutic drug development, especially for treatment using convalescent plasma, thus temporarily increasing demand.

LATEST TREND

"Development in Personalized Medicine to Drive Market Growth"

The market for blood plasma is increasingly in demand for plasma-based therapies for rare and chronic diseases. With the increase in personalization in medicine, the development of specialized immunoglobulins and clotting factors specific to the patient profile has spurred innovation in plasma products. In addition, companies have recently been adopting more sophisticated fractionation technologies that improve plasma components' yield and purity. Increased awareness of plasma as an essential tool in controlling disease, along with strategically developing partnerships to expand a plasma collection network across international markets, is driving more market growth and access toward plasma-based treatments, particularly in developing nations.

• 

  Request a Free Sample to learn more about this report

BLOOD PLASMA MARKET SEGMENTATION

BY TYPE

Based on Type, the global market can be categorized into Immunoglobulin, Albumin, Protease Inhibitors, Coagulation Factor Concentrates, Others:

• Immunoglobulin: Immunoglobulin is plasma-derived products for mainly managing immune deficiencies and auto immune conditions. They dominate blood plasma markets because they play such a significant role in managing chronic conditions as demand continues to grow in this direction of immunotherapy.

• Albumin: Albumin is used in the treatment of diseases of the liver, shock, burns, and serious hemorrhage. It is also used in the preparations of drugs and as a volume expander in blood. An increased demand from hospitals, mainly in emergency care, supports the growth of the albumin segment.

• Protease Inhibitors: This plasma-derived protein falls into a class of proteins which are most used in treatment, either alone or with others like C1-INH for some diseases, notably hereditary angioedema. That segment has constant demand-both from a rise of treatments for rare diseases but also focus on biologic therapeutics.

• Coagulation Factor Concentrates: Coagulation factor concentrates are another very significant segment of this market, as they are essential for the treatment of hemophilia and other bleeding disorders. They are helpful in managing disorders of blood clotting and have found wider applications in clinical settings with the advancements in recombinant technologies.

• Others: This is a class of plasma-derived products applied in diverse therapeutic areas, such as critical care, regenerative medicine, and cell therapy. Advances in plasma fractionation and the diversification of products under this category are also helping to boost the market growth.

BY APPLICATION

Based on application, the global market can be categorized into Hospitals and Clinics, Research Laboratories, Academic Institutions:

• Specialty Clinics and Hospitals: Specialty clinics and hospitals are a very important source for MRD testing in the planning, monitoring, and assessment of treatment of patients with hematologic malignancies. As interest in its utility in guiding modification of treatment and improving outcome and overall management of patients develops, hospitals embrace MRD testing.

• Diagnostic Laboratories: This laboratory type employs high technology diagnostic apparatus and specialized machinery to execute high volume testing MRD. In this kind of laboratory setup, laboratories are of great significance for health care providers. Labs have ensured reliable and speediest results for the provider regarding residual disease and accuracy in its detection.

• Research Institutes: They primarily use MRD testing in clinical research to advance their knowledge of relapse of cancer, treatment resistance, and therapeutic efficacy. These institutes are always pioneering new technologies and methods in MRD testing through their research.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

DRIVING FACTORS

"Increasing Prevalence of Chronic Diseases and Increasing Surgical Procedures and Emergency Care Needs are Likely to Boost the Market"

A factor in Blood Plasma Market Growth is increasing cases of chronic diseases, including hemophilia, liver disorders, and immune deficiencies, form a significant driving force for the blood plasma market. Most of these diseases require plasma-derived therapies, which leads to increased demand for products such as immunoglobulins and coagulation factor concentrates. It would expand vastly as more cases are being diagnosed and treated in much larger numbers. More surgeries as well as trauma cases would require immediate blood plasma transfusions and therapies within hospitals and clinics. The critical care part speaks of using plasma products even more significantly at a time of emergency while being supportive of the patient outcome and hence of rising recoveries.

"Technological Advancements in Plasma Collection and Processing to Expand the Market"

Innovations in blood plasma collection and processing technologies are improving the efficiency and safety of plasma-derived therapies. Better methods for plasma separation, storage, and testing have led to higher product yields and better quality, increasing the availability of essential plasma products in the market.

RESTRAINING FACTOR

"High Costs Associated with Plasma Collection and Production to Potentially Impede Market Growth"

One of the key difficulties that the blood plasma market faces is the exorbitant cost of collecting and manufacturing plasma. These procedures require specialized facilities, professional staff, and very tight quality control measures. Therefore, these costs tend to push up the cost of plasma-derived products. It might limit access for the patient and healthcare providers especially in low-income regions. This financial barrier can put a restraining element on the progress of the market since it may prevent critical treatments from being supplied to the patients.

OPPORTUNITY

"Rising Demand for Immunoglobulin Therapies to Create Opportunity for the Product in the Market"

Increased prevalence of autoimmune diseases, immunodeficiency, and other chronic disorders is the driving force for the growing demand for blood plasma-derived immunoglobulin therapies. Continued recognition by health care providers and researchers into their effectiveness in treating so many medical conditions make the scope open for manufacturers to expand their product line and find new immunoglobulin-based treatments. That market trend offers great commercial opportunities for companies that would easily scale up production and find advanced therapies to improve outcomes for patients and meet the rising demand in the healthcare field.

CHALLENGE

"Supply Chain Disruptions and Regulations Could Be a Potential Challenge for Consumers"

Supply chain disruption and strict regulatory requirements are major challenges to the blood plasma market. Blood plasma collection and processing is a complex logistical process, vulnerable to many factors such as transport delay, donor availability, and health regulations compliance. In addition, regional regulatory requirements may delay product approval and entry into the market, thus posing risks for manufacturers and suppliers. Such barriers might further postpone the availability of blood plasma products and potentially restrict the supply in other cases, which could possibly result in gaps in treatments that can negatively affect patient care.

• 

  Request a Free Sample to learn more about this report

BLOOD PLASMA MARKET REGIONAL INSIGHTS

• NORTH AMERICA

Blood plasma products are the largest product category in North America, especially United States Blood Plasma Market due to rising rates of chronic diseases, which in turn increase demand for immunoglobulin therapies. The established healthcare infrastructure in the United States along with several plasma collection centers located there has increased plasma-derived therapies availability. Moreover, better technologies and higher research activities and investments in the region contribute to growth. Regulatory support and reimbursement policy also supports the growth of the North American blood plasma market.

• EUROPE

The demand for blood plasma in the European market is gradually escalating due to an increasing incidence rate of bleeding disorders and its associated products. The major revenue contributors are Germany, France, and the UK with a sound health care infrastructural backbone and increasing plasma therapy awareness. Regional differences in plasma collection and variances in the regulatory environments will pose a huge challenge in this market. Despite all this, the improvement efforts of the European Union in setting plasma collection and processing standards are likely to influence the market dynamics.

• ASIA

This market is expected to have a high growth rate, due to the rapid increasing demand for therapeutic plasma products, as well as for growing health care expenditure. A growing awareness of plasma derived therapy among the population brings forward the countries of China and India as the emergent key players. This, however, does present certain challenges in the markets - the lack of any established plasma collection networks in several countries and regulatory restrictions. Growth factors for the market in the region include initiatives for the development of healthcare infrastructure and government efforts to promote plasma donation.

LIST OF TOP BLOOD PLASMA MARKET COMPANIES

• Shanghai Raas (China)
• Octapharma (Switzerland)
• Grifols (Spain)
• CSL (Australia)
• TCS Biosciences (UK)
• Sanquin (Netherlands)
• ADMA Biologics (USA)
• Cerus Corp (USA)
• Baxter International (USA)

KEY INDUSTY DEVELOPMENT

September 2024: CSL Limited has unveiled the latest breakthroughs in blood plasma processing technology at a global healthcare conference in London. The company unveiled an innovative automated system that streamlines the plasma collection and purification process to be more efficient and safer. This cutting-edge technology will reduce processing time by 30%, significantly increasing availability of vital plasma-derived therapies. CSL highlights that such improvements form part of its commitment toward fulfilling the ever-growing demand for immunoglobulin products and in helping patients around the world while plasma management stays at the highest levels of quality.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.